R
Riccardo Marconcini
Researcher at University of Pisa
Publications - 58
Citations - 1696
Riccardo Marconcini is an academic researcher from University of Pisa. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 45 publications receiving 1094 citations.
Papers
More filters
Journal ArticleDOI
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini,Melissa Bersanelli,Sebastiano Buti,Katia Cannita,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Maria Michiara,Pietro Di Marino,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Federica Pergolesi,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Andrea De Giglio,Daniela Iacono,Alain Gelibter,Mario Occhipinti,Alessandro Parisi,Giampiero Porzio,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella,Clara Natoli +44 more
TL;DR: Overweight could be considered a tumorigenic immune-dysfunction that could be effectively reversed by ICIs and BMI could be a useful predictive tool in clinical practice and a stratification factor in prospective clinical trials with ICIs.
Journal ArticleDOI
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
Marzia Del Re,Riccardo Marconcini,Giulia Pasquini,Eleonora Rofi,Caterina Vivaldi,Francesco Bloise,Giuliana Restante,Elena Arrigoni,Chiara Caparello,Maria Grazia Bianco,Stefania Crucitta,Iacopo Petrini,Enrico Vasile,Alfredo Falcone,Romano Danesi +14 more
TL;DR: This corrects the article DOI: 10.1038/bjc2017.85 to BJC 2017, which indicates the paper was originally published in British Journal of Criminal Justice in 2017.
Journal ArticleDOI
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
Paolo A. Ascierto,Ester Simeone,Vanna Chiarion Sileni,Jacopo Pigozzo,Michele Maio,Maresa Altomonte,Michele Del Vecchio,Lorenza Di Guardo,Paolo Marchetti,Ruggero Ridolfi,Francesco Cognetti,Alessandro Testori,Maria Grazia Bernengo,Michele Guida,Riccardo Marconcini,Mario Mandalà,Carolina Cimminiello,Gaetana Rinaldi,Massimo Aglietta,Paola Queirolo +19 more
TL;DR: Data from this large cohort of patients support clinical trial evidence that ipilimumab can induce durable disease control and long-term survival in patients who have failed to respond to prior treatment.
Journal ArticleDOI
Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma
Michele Del Vecchio,Lorenza Di Guardo,Paolo A. Ascierto,Antonio M. Grimaldi,Vanna Chiarion Sileni,Jacopo Pigozzo,Virginia Ferraresi,Carmen Nuzzo,Gaetana Rinaldi,Alessandro Testori,Pier Francesco Ferrucci,Paolo Marchetti,Federica De Galitiis,Paola Queirolo,Elena Tornari,Riccardo Marconcini,Luana Calabrò,Michele Maio +17 more
TL;DR: Ipilimumab may be a feasible treatment option in pretreated patients with metastatic mucosal melanoma, and warrants further investigation in prospective clinical trials.
Journal ArticleDOI
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini,Sebastiano Buti,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Melissa Bersanelli,Maria Michiara,Antonino Grassadonia,Davide Brocco,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Roberto Sabbatini,Sergio Bracarda,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Daniela Iacono,Maria Rita Migliorino,Antonio Rossi,Giampiero Porzio,Katia Cannita,Valeria Ciciarelli,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella +44 more
TL;DR: The finding of a greater incidence of irAEs among female patients ranks among the "hot topics" in gender-related differences in immuno-oncology.